Pan-cancer DNMT3A mutation rate

Biomarker

1 paper1 finding

In silico1

Upstream

Correction for blood-derived coding calls

downin silico1−45% reduction

1 study

correction for blood-derived coding calls decrease pan-cancer DNMT3A mutation rate in silico (45% reduction).
“Correction lowers the pan-cancer DNMT3A rate by 45%”
In silicoExclusion of blood-derived calls before patient-keyed aggregation
Blood mutations skew pooled human cancer mutation data
medRxiv12 Oct 2026Preprint

Latest

1 in 12 months

medRxiv3 h

Blood mutations skew pooled human cancer mutation data

For one gene involved in DNA modification, 52.8% of patients flagged as carrying a mutation had no tumour-derived mutation in that gene.For one gene involved in DNA modification, 52.8% of patients flagged as carrying a mutation had no tumour-derived mutation in that gene.

Preprint: computational studyMechanisms

Paper

Pan-cancer DNMT3A mutation rate

Upstream

Latest

Blood mutations skew pooled human cancer mutation data

Related